直接口服抗凝药治疗静脉血栓栓塞性疾病
本文批判性综述直接口服抗凝药(DOAC)治疗静脉血栓栓塞性疾病(VTE)的现有证据,并分析各药物特性。综述指出,DOAC 在降低 VTE 复发方面与标准治疗(肠外抗凝后序贯维生素 K 拮抗剂)同样有效,且大出血风险更低,是标准治疗之外有吸引力的选择。
要点
- DOAC 降低 VTE 复发的疗效与标准治疗相当。
- DOAC 大出血风险低于标准治疗。
- DOAC 是 VTE 治疗中标准治疗之外有吸引力的替代方案。
核心结论
- DOAC 是治疗静脉血栓栓塞症的有吸引力的标准治疗替代方案。
研究设计与样本
- 本文为文献综述,旨在批判性评价 DOAC 治疗静脉血栓栓塞性疾病的现有证据,并分析每种药物的具体特点。
主要发现
- DOAC 较标准治疗具有诸多优势。
- DOAC 降低 VTE 复发的疗效与标准治疗相当,且大出血风险更低。
临床怎么用
- 对非肿瘤患者的 VTE,可考虑以 DOAC 替代传统肠外抗凝后序贯维生素 K 拮抗剂的方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anticoagulation is the treatment of choice in the management of venous thromboembolic disease. This approach is applied to reduce mortality and the risk of recurrences and associated complications. Standard therapy for non-oncologic patients has traditionally been based on parenteral anticoagulation followed by vitamin K antagonists. However, this approach has many limitations. METHODS: The aim of this manuscript was to critically review current evidence on the use of direct oral anticoagulants in the treatment of venous thromboembolic disease by analyzing the specific characteristics of each drug. RESULTS: Direct oral anticoagulants have many advantages over standard therapy. While they are equally effective as standard therapy for reducing the possibility of recurrence of venous thromboembolic disease, they carry a lower risk of major bleeding. CONCLUSIONS: Direct oral anticoagulants are an attractive alternative to standard therapy for the treatment of venous thromboembolism.
引用
- Salmerón Febres LM, Cuenca Manteca J. Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease. Ann Vasc Surg. 2017. PMID: 28390916. doi:10.1016/j.avsg.2017.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。